New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
The planned bioprocessing facility would support commercial manufacturing for biotech and pharmaceutical customers across Asia-Pacific.
Investment further strengthens Merck's "Big 3," the key drivers for increasing Group sales to approximately € 25 billion by 2025
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
The transaction is expected to close in the first quarter of 2022
The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)